Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.

1.0 mg or oral 14 mg doses) versus active comparators (SUSTAIN 3 and PIONEER 2, respectively), although these differences did not reach statistical significance (p > 0.05; Additional file 1 : Fig.

also in 111,027 other papers

In PIONEER 5, there was a nonsignificant trend of reduction, as the ETR at week 26 for oral semaglutide versus placebo was 0.83 [95% CI, 0.67–1.03]; p = 0.08; Fig. 1 .

also in 5,406 other papers